title: State of the art in developing allergen vaccines in Cuba: prospects of novel adjuvanted vaccines.
abstract: Standardized allergen vaccines have been developed and registered as biopharmaceutical products in Cuba. Three different vaccines were obtained from the most relevant allergenic mite species: Dermatophagoides pteronvssinus, Dermatophagoides siboney, and Blomia tropicalis. Immuno-analytical methods based on murine monoclonal antibodies and human IgE antibodies were developed for assessing allergenic potency, composition, and stability. Preclinical and clinical studies showed efficacy and safety in diagnostic prick-tests and subcutaneous immunotherapy in asthmatic patients. New approaches are now undertaken in order to develop new adjuvanted formulations based on liposomes or proteoliposomes from Neisseria meningitidis, and purified allergens; aiming to overcome the drawbacks of conventional immunotherapy.
authors.affiliation: Allergens Department, Centro Nacional de Biopreparados, P.O. Bor 6048, Havana 10600, Cuba. labrada@biocen.cu
authors.forename: Alexis
authors.initials: A
authors.lastname: Labrada
authors.forename: Elisa
authors.initials: E
authors.lastname: Facenda
authors.forename: Raul L
authors.initials: RL
authors.lastname: Castro
authors.forename: Bárbara
authors.initials: B
authors.lastname: Fernández
authors.forename: Keiko
authors.initials: K
authors.lastname: Uyema
authors.forename: Minerva
authors.initials: M
authors.lastname: Sewer
authors.forename: Rosa E
authors.initials: RE
authors.lastname: Aranda
authors.forename: Arelis
authors.initials: A
authors.lastname: Más
authors.forename: Bárbara
authors.initials: B
authors.lastname: Navarro
authors.forename: Olga
authors.initials: O
authors.lastname: Jorge
authors.forename: Ivette
authors.initials: I
authors.lastname: Novoa
authors.forename: José
authors.initials: J
authors.lastname: Díaz
authors.forename: Virgilio
authors.initials: V
authors.lastname: Bourg
mesh_terms: D000276:Adjuvants, Immunologic; D000485:Allergens / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology* / Q000302:isolation & purification; D000818:Animals; D003462:Cuba; D003888:Desensitization, Immunologic / Q000009:adverse effects; D008081:Liposomes / Q000494:pharmacology; D051379:Mice; D008925:Mites / Q000276:immunology*; D009345:Neisseria meningitidis; D011510:Proteolipids / Q000494:pharmacology; D014612:Vaccines / Q000276:immunology / Q000627:therapeutic use
chemical_list: D000276:Adjuvants, Immunologic; D000485:Allergens; D008081:Liposomes; D011510:Proteolipids; D014612:Vaccines; C020485:proteoliposomes